Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this Phase I study is to determine the safety of a drug called dexmedetomidine (DEX) as part of a balanced general anesthetic and sedative strategy for neonates and infants undergoing corrective cardiac surgery that requires the use of cardiopulmonary bypass for congenital cardiac problems. This study will also design and validate a dosing schema for the use of DEX as described above.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Neonate dosing cohort 1 | Experimental | Neonate dexmedetomidine dosing cohort 1 |
|
| Neonate dosing cohort 2 | Experimental | Neonate dexmedetomidine dosing cohort 2 |
|
| Neonate dosing cohort 3 | Experimental | Neonate dexmedetomidine dosing cohort 3 |
|
| Neonate dosing cohort 4 | Experimental | Neonate dexmedetomidine dosing cohort 4 |
|
| Neonate dosing cohort 5 | Experimental | Neonate dexmedetomidine dosing cohort 5 |
|
| Infant dosing cohort 1 | Experimental | Infant dexmedetomidine dosing cohort 1 |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dexmedetomidine | Drug |
|
| Measure | Description | Time Frame |
|---|---|---|
| The occurrence of a safety event that is possibly, probably or definitely related to DEX administration | The occurrence of any of the following that is possibly, probably, or definitely related to DEX administration:
Both the DEX dose, and DEX exposure will be assessed for associations with the primary outcome. | Within 4 hours after DEX adminstration |
| Measure | Description | Time Frame |
|---|---|---|
| Plasma concentration of DEX | Plasma concentrations of dex obtained intraoperatively and up to 36 hours post-operatively will be used to create drug dosing models. These models will then be evaluated to determine how effective they are at achieving targeted plasma concentration levels. | Intraoperatively and up to 36 hours post-operatively |
Not provided
Inclusion Criteria:
Exclusion Criteria:
1. Less than 37 completed weeks' gestational age at birth for the Neonatal age group (0-21 days); less than 36 completed weeks' gestational age at birth for the Infant age group (22-180 days).
2. Enrollment in the PHN Collaborative Learning Study, if tetralogy of Fallot 91-180 days of age only.
3. Known or suspected hepatic dysfunction; AST and ALT >3X upper limit of normal at the time of screening within 72 hours of operation.
4. Known or suspected renal dysfunction; serum creatinine > 0.8 mg/dL after 7 days of age, >1.2 mg/dL if <7 days of age, within 72 hours of operation.
5. Preoperative administration of DEX or clonidine within 72 hours of operation.
6. Major congenital anomaly(ies) outside the cardiovascular system that in the investigator's opinion would potentially affect safety or pharmacokinetics.
7. Preoperative central nervous system injury resulting in clinical signs and symptoms: coma, seizures, hemiparesis.
8. Planned period of deep hypothermic circulatory arrest. 9. History of second or third degree heart block. 10. Sinus or junctional bradycardia below 80 BPM sustained for greater than 15 minutes within 72 hours of operation. 11. Junctional rhythm sustained for greater than 15 minutes within 72 hours of operation.
12. Hypotension defined as mean arterial blood pressure below 35 mm Hg for 0-21 day old neonatal patients, and below 40 mm Hg for 22-180 day old infant patients sustained for greater than 15 minutes within 72 hours of operation.
13. History of cardiac arrest or ECMO cannulation.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Boston Children's Hospital | Boston | Massachusetts | 02111 | United States | ||
| University of Michigan |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 31623840 | Derived | Zuppa AF, Nicolson SC, Wilder NS, Ibla JC, Gottlieb EA, Burns KM, Stylianou M, Trachtenberg F, Ni H, Skeen TH, Andropoulos DB; Pediatric Heart Network Investigators. Results of a phase 1 multicentre investigation of dexmedetomidine bolus and infusion in corrective infant cardiac surgery. Br J Anaesth. 2019 Dec;123(6):839-852. doi: 10.1016/j.bja.2019.06.026. Epub 2019 Oct 14. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Infant dosing cohort 2 | Experimental | Infant dexmedetomidine dosing cohort 2 |
|
| Infant dosing cohort 3 | Experimental | Infant dexmedetomidine dosing cohort 3 |
|
| Infant dosing cohort 4 | Experimental | Infant dexmedetomidine dosing cohort 4 |
|
| Infant dosing cohort 5 | Experimental | Infant dexmedetomidine dosing cohort 5 |
|
|
| Ann Arbor |
| Michigan |
| 48109 |
| United States |
| Childrens Hospital of Philadelphia | Philadelphia | Pennsylvania | 19104 | United States |
| Texas Children's Hospital | Houston | Texas | 77030 | United States |
| ID | Term |
|---|---|
| D014188 | Transposition of Great Vessels |
| D013771 | Tetralogy of Fallot |
| D006345 | Heart Septal Defects, Ventricular |
| ID | Term |
|---|---|
| D006330 | Heart Defects, Congenital |
| D018376 | Cardiovascular Abnormalities |
| D002318 | Cardiovascular Diseases |
| D006331 | Heart Diseases |
| D000013 | Congenital Abnormalities |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D006343 | Heart Septal Defects |
Not provided
Not provided
| ID | Term |
|---|---|
| D020927 | Dexmedetomidine |
| ID | Term |
|---|---|
| D007093 | Imidazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided